RSS-Feed abonnieren
DOI: 10.1055/s-0040-1708842
Thrombocytopenia in Pregnancy: Approach to Diagnosis and Management
![](https://www.thieme-connect.de/media/sth/202003/lookinside/thumbnails/10-1055-s-0040-1708842_02745-1.jpg)
Abstract
The impact of thrombocytopenia varies widely depending on the underlying pathophysiology driving it. The biggest challenge in managing thrombocytopenia in pregnancy is accurately identifying the responsible pathophysiology—a task made difficult given the tremendous overlap in clinical and laboratory abnormalities associated with different thrombocytopenia processes. The most common etiologies of thrombocytopenia in pregnancy range from physiology deemed benign to those that are life-threatening to the mother and fetus. Even in cases in which the responsible etiology is deemed benign, such as gestational thrombocytopenia, there are still implications for the management of labor and delivery, a time where hemostatic challenges may prove life-threatening. In most institutions, a minimum platelet count will be mandated for epidural anesthesia to be deemed a safe option. The causes of thrombocytopenia can also include diagnoses that are pregnancy-specific (such as preeclampsia or gestational thrombocytopenia), potentially triggered by pregnancy (such as thrombotic thrombocytopenic purpura), or unrelated to or predating the pregnancy (such as liver disease, infections, or immune thrombocytopenia purpura). It is imperative that the source of thrombocytopenia is identified accurately and expeditiously, as intervention can range from observation alone to urgent fetal delivery. In this review, the approach to diagnosis and the pathophysiological mechanisms of the most common etiologies of thrombocytopenia in pregnancy and associated management issues are presented.
Publikationsverlauf
Publikationsdatum:
07. April 2020 (online)
© 2020. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Fogerty AE. Thrombocytopenia in pregnancy: mechanisms and management. Transfus Med Rev 2018; 32 (04) 225-229
- 2 McCrae KR. Thrombocytopenia in pregnancy: differential diagnosis, pathogenesis, and management. Blood Rev 2003; 17 (01) 7-14
- 3 Zhang X, Zhao Y, Li X. et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget 2016; 7 (07) 7489-7496
- 4 Freedman J, Musclow E, Garvey B, Abbott D. Unexplained periparturient thrombocytopenia. Am J Hematol 1986; 21 (04) 397-407
- 5 Lescale KB, Eddleman KA, Cines DB. et al. Antiplatelet antibody testing in thrombocytopenic pregnant women. Am J ObstetGynecol 1996; 174 (03) 1014-1018
- 6 Jodkowska A, Martynowicz H, Kaczmarek-Wdowiak B, Mazur G. Thrombocytopenia in pregnancy - pathogenesis and diagnostic approach. PostepyHig Med Dosw 2015; 69: 1215-1221
- 7 Drury-Stewart DN, Lannert KW, Chung DW. et al. Complex changes in von Willebrand factor-associated parameters are acquired during uncomplicated pregnancy. PLoS One 2014; 9 (11) e112935
- 8 Sánchez-Luceros A, Farías CE, Amaral MM. et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. ThrombHaemost 2004; 92 (06) 1320-1326
- 9 Lattuada A, Rossi E, Calzarossa C, Candolfi R, Mannucci PM. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003; 88 (09) 1029-1034
- 10 Stepanian A, Cohen-Moatti M, Sanglier T. et al; ECLAXIR Study Group. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. ArteriosclerThrombVascBiol 2011; 31 (07) 1703-1709
- 11 Aref S, Goda H. Increased VWF antigen levels and decreased ADAMTS13 activity in preeclampsia. Hematology 2013; 18 (04) 237-241
- 12 Reese JA, Peck JD, McIntosh JJ, Vesely SK, George JN. Platelet counts in women with normal pregnancies: a systematic review. Am J Hematol 2017; 92 (11) 1224-1232
- 13 Reese JA, Peck JD, Deschamps DR. et al. Platelet counts during pregnancy. N Engl J Med 2018; 379 (01) 32-43
- 14 Ruggeri M, Schiavotto C, Castaman G, Tosetto A, Rodeghiero F. Gestational thrombocytopenia: a prospective study. Haematologica 1997; 82 (03) 341-342
- 15 Anteby E, Shalev O. Clinical relevance of gestational thrombocytopenia of < 100,000/microliters. Am J Hematol 1994; 47 (02) 118-122
- 16 Wang X, Xu Y, Luo W. et al. Thrombocytopenia in pregnancy with different diagnoses: differential clinical features, treatments, and outcomes. Medicine (Baltimore) 2017; 96 (29) e7561
- 17 Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J ThrombHaemost 2006; 4 (11) 2377-2383
- 18 Stavrou E, McCrae KR. Immune thrombocytopenia in pregnancy. HematolOncolClin North Am 2009; 23 (06) 1299-1316
- 19 Provan D, Stasi R, Newland AC. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
- 20 McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J ThrombHaemost 2003; 1 (03) 485-491
- 21 Khaspekova SG, Shustova ON, Golubeva NV, Naimushin YA, Larina LE, Mazurov AV. Circulating antiplatelet antibodies in pregnant women with immune thrombocytopenic purpura as predictors of thrombocytopenia in the newborns. Platelets 2019; 30 (08) 1008-1012
- 22 Webert KE, Mittal R, Sigouin C, Heddle NM, Kelton JG. A retrospective 11-year analysis of obstetric patients with idiopathic thrombocytopenic purpura. Blood 2003; 102 (13) 4306-4311
- 23 Veneri D, Franchini M, Raffaelli R. et al. Idiopathic thrombocytopenic purpura in pregnancy: analysis of 43 consecutive cases followed at a single Italian institution. Ann Hematol 2006; 85 (08) 552-554
- 24 Sun D, Shehata N, Ye XY. et al. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood 2016; 128 (10) 1329-1335
- 25 Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183 (07) 796-804
- 26 Park-Wyllie L, Mazzotta P, Pastuszak A. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62 (06) 385-392
- 27 Myers B. Diagnosis and management of maternal thrombocytopenia in pregnancy. Br J Haematol 2012; 158 (01) 3-15
- 28 Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117 (05) 1499-1506
- 29 Purushothaman J, Puthumana KJ, Kumar A, Innah SJ, Gilvaz S. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. Asian J TransfusSci 2016; 10 (02) 155-158
- 30 Kong Z, Qin P, Xiao S. et al. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy. Blood 2017; 130 (09) 1097-1103
- 31 Milne F, Redman C, Walker J. et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330 (7491): 576-580
- 32 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. ObstetGynecol 2013; 122 (05) 1122-1131
- 33 MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. ObstetGynecol 2001; 97 (04) 533-538
- 34 Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20 (01) IX-XIV
- 35 Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J ObstetGynecol 2013; 209 (06) 544.e1-544.e12
- 36 Karumanchi SA, Maynard SE, Stillman IE, Epstein FH, Sukhatme VP. Preeclampsia: a renal perspective. Kidney Int 2005; 67 (06) 2101-2113
- 37 Keiser SD, Owens MY, Parrish MR. et al. HELLP syndrome with and without eclampsia. Am J Perinatol 2011; 28 (03) 187-194
- 38 Martin Jr JN, Rose CH, Briery CM. Understanding and managing HELLP syndrome: the integral role of aggressive glucocorticoids for mother and child. Am J ObstetGynecol 2006; 195 (04) 914-934
- 39 Wallace K, Martin Jr JN, Tam Tam K. et al. Seeking the mechanism(s) of action for corticosteroids in HELLP syndrome: SMASH study. Am J ObstetGynecol 2013; 208 (05) 380.e1-380.e8
- 40 Kohli S, Ranjan S, Hoffmann J. et al. Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts. Blood 2016; 128 (17) 2153-2164
- 41 Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019 (10) DOI: 10.1002/14651858.CD004659.pub3. [epub ahead of print]
- 42 Mallampati D, Grobman W, Rouse DJ, Werner EF. Strategies for prescribing aspirin to prevent preeclampsia. ObstetGynecol 2019; 134 (03) 537-544
- 43 Soto E, Romero R, Kusanovic JP. et al. Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med 2012; 25 (05) 498-507
- 44 Wang A, Rana S, Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) 2009; 24: 147-158
- 45 Levine RJ, Maynard SE, Qian C. et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683
- 46 Verlohren S, Galindo A, Schlembach D. et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J ObstetGynecol 2010; 202 (02) 161.e1-161.e11
- 47 Verlohren S, Herraiz I, Lapaire O. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J ObstetGynecol 2012; 206 (01) 58.e1-58.e8
- 48 Villa PM, Hämäläinen E, Mäki A. et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 2013; 13: 110
- 49 Vaught AJ, Gavriilaki E, Hueppchen N. et al. Direct evidence of complement activation in HELLP syndrome: a link to atypical hemolytic uremic syndrome. ExpHematol 2016; 44 (05) 390-398
- 50 Burwick RM, Feinberg BB. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013; 34 (02) 201-203
- 51 Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. ObstetGynecol 2004; 103 (5 Pt 1): 981-991
- 52 Nelson DB, Yost NP, Cunningham FG. Acute fatty liver of pregnancy: clinical outcomes and expected duration of recovery. Am J ObstetGynecol 2013; 209 (05) 456.e1-456.e7
- 53 Castro MA, Fassett MJ, Reynolds TB, Shaw KJ, Goodwin TM. Reversible peripartum liver failure: a new perspective on the diagnosis, treatment, and cause of acute fatty liver of pregnancy, based on 28 consecutive cases. Am J ObstetGynecol 1999; 181 (02) 389-395
- 54 Knight M, Nelson-Piercy C, Kurinczuk JJ, Spark P, Brocklehurst P. UK Obstetric Surveillance System. A prospective national study of acute fatty liver of pregnancy in the UK. Gut 2008; 57 (07) 951-956
- 55 Ch'ng CL, Morgan M, Hainsworth I, Kingham JG. Prospective study of liver dysfunction in pregnancy in Southwest Wales. Gut 2002; 51 (06) 876-880
- 56 Bacq Y. Liver diseases unique to pregnancy: a 2010 update. Clin Res HepatolGastroenterol 2011; 35 (03) 182-193
- 57 Davidson KM, Simpson LL, Knox TA, D'Alton ME. Acute fatty liver of pregnancy in triplet gestation. ObstetGynecol 1998; 91 (5 Pt 2): 806-808
- 58 Creasy RK, Resnick R, Iams JD, Lockwood CJ, Moore TR. Creasy and Resnick's Maternal-Fetal Medicine: Principles and Practice. 6th ed. Philadelphia, PA: Saunders/Elsevier; 2009
- 59 Liu J, Ghaziani TT, Wolf JL. Acute fatty liver disease of pregnancy: updates in pathogenesis, diagnosis, and management. Am J Gastroenterol 2017; 112 (06) 838-846
- 60 Chen H, Yuan L, Tan J, Liu Y, Zhang J. Severe liver disease in pregnancy. Int J GynaecolObstet 2008; 101 (03) 277-280
- 61 Scully M. Thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome microangiopathy in pregnancy. SeminThrombHemost 2016; 42 (07) 774-779
- 62 Scully M, Thomas M, Underwood M. et al; collaborators of the UK TTP Registry. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124 (02) 211-219
- 63 Vesely SK, Li X, McMinn JR, Terrell DR, George JN. Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion 2004; 44 (08) 1149-1158
- 64 Fakhouri F, Roumenina L, Provot F. et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am SocNephrol 2010; 21 (05) 859-867
- 65 Kelly RJ, Höchsmann B, Szer J. et al. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015; 373 (11) 1032-1039